What exactly is a mesenchymal cell and what does the acronym MSC stand for these days? I took a stab recently at discussing mesenchymal cells and the MSC acronym so check that out. There is a great need for standards on MSCs and the products out there being marketed as MSCs are probably in reality […]
Weekly reads: MSC, p53, EuroGCT, fake fish, K27M CAR-T Read More »
I’ve ended up learning a lot about multiple sclerosis (MS) while writing The Niche for the past twelve plus years, but I’ve never seen anything like the new research linking EBV and MS. EBV stands for Epstein Barr Virus. The reason I’ve learned much more about MS while writing here is that there has been
Stronger link between EBV and MS brings concrete clinical hope Read More »
The big news of the week was the launch of Altos labs and their ambitious plan to tackle aging through cell therapies. Altos has recruited a large number of top cell biologists away from academia. That team plus top biotech execs and a $3B war chest make Altos one to watch in coming years. I
Weekly reads: aging, CRISPR delivery, hair, oocytes, paralysis Read More »
The fact that a person for the first time has received a heart transplant from a pig and it was a genetically modified pig made big news this week. Organ transplant waiting lists are a huge problem so if this kind of approach can be proven to be safe and effective, it would be a
Recommended reads: pig heart transplant, lasers, $11K pub fee Read More »
The amount of biomedical science hype out there is mindboggling at times, but some media or other items really take the cake for being exceptionally bad. Today’s post highlights the worst of the year 2021 as the candidates for my annual The Screamers science hype award. Click on the link in the previous sentence to
What if you could get 8-year grants to do whatever biomedical research you wanted? This sounds like a dream for many of us in the life sciences, but the first news item this week is all about such a potential new funding approach. The item especially caught my eye as I’m going to be doing
Weekly reads: hydra heads, iblastoids, new 8-year grants Read More »
If you celebrate the Thanksgiving holiday I hope you had a nice one and, right before it started a new article popped on the scene about the CRISPR babies. Before we discuss those three gene-edited people, who are now growing up into little kids, we hit a milestone on our YouTube Stem Cell Channel with
Regenerative reads: 3 CRISPR babies, FDA warning, diabetes, pubs Read More »
Great ideas and talented scientists are not enough as biomedical research needs funding and here in the U.S. that means having R01 grant success. The trends since 1995 are slowly heading the wrong way. The average age of getting your first R01 grant keeps getting older. There is also still a bit of a possible
Weekly reads: R01 grant trends, DPPA4, adult human neurogenesis debate Read More »
Liveyon is a cord blood product marketer that distributed a batch of cells a couple of years back that led to many patients being hospitalized with infections. Some had sepsis and ended up in the ICU. It was thought at the time that about a dozen patients who had been injected with the Liveyon product
Liveyon product hurt many more patients says new CDC study Read More »
This week marked the release of new draft FDA guidance on cell and gene therapies. Is the FDA kind of like the guidance counselor at school or more like the principal? It probably depends on many factors. I also find it funny how pretty much everyone in academia and biotech industry works to be compliant
Weekly reads: New FDA guidance, brains, MSCs, senescence Read More »